Maduck Sean sold $2.0M of CORT

Maduck Sean sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $81.85 ($81.42–$82.68, $2.05M total) across 3 trades over 2026-11-02 to 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Nov 5, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, prompting short sellers.

02

Market read

Insider sales are closely watched by traders; this filing provides fresh data that could affect short‑term price action.

03

What to watch

Potential upcoming clinical data releases that could offset the negative signal.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑11‑04

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Insider Maduck Sean sold 25,000 shares for $2.0M via a 10b5‑1 plan, reducing his stake to 9,938 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

A $2M sale by an insider is material for a small‑cap biotech and often leads to short‑term price weakness.

Market effects

May raise caution for other small‑cap biotech stocks with recent insider sales.

Limited to U.S. markets; no broader regional effect.

Minimal global impact.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect company fundamentals.

Key entities

  • Corcept Therapeutics Inc

    Biopharmaceutical company developing cortisol‑targeting therapies.

  • Maduck Sean

    Officer/director of Corcept Therapeutics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.